BiotechTube

zolinza/vorinostat

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Children With Relapsed Solid Tumor, Lymphoma or Leukemia

Conditions

Children With Relapsed Solid Tumor, Lymphoma or Leukemia

Trial Timeline

Mar 1, 2012 → Mar 24, 2017

NCT ID
NCT01422499

About zolinza/vorinostat

zolinza/vorinostat is a phase 1/2 stage product being developed by Merck for Children With Relapsed Solid Tumor, Lymphoma or Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01422499. Target conditions include Children With Relapsed Solid Tumor, Lymphoma or Leukemia.

What happened to similar drugs?

0 of 13 similar drugs in Children With Relapsed Solid Tumor, Lymphoma or Leukemia were approved

Approved (0) Terminated (1) Active (12)
🔄Exenatide Once Weekly + PlaceboAstraZenecaPhase 3
🔄MEDI3250 + PlaceboAstraZenecaPhase 3
🔄MEDI3250AstraZenecaPhase 3
❌Budesonide Formoterol Drug Combination + nebulisation of terbutalineAstraZenecaPhase 3
🔄Saizen® A + Saizen® BMerckPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄HydroxyureaNovartisPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01422499Phase 1/2Completed

Competing Products

20 competing products in Children With Relapsed Solid Tumor, Lymphoma or Leukemia

See all competitors
ProductCompanyStageHype Score
Quizartinib + Etoposide + Dexrazoxane + Mitoxantrone + Cytarabine + Methotrexate + Daunorubicin + FludarabineDaiichi SankyoPhase 2
42
RSS0393 OintmentJiangsu Hengrui MedicinePhase 2
42
Ceftazidime-avibactamAbbViePhase 1
21
Exenatide Once Weekly + PlaceboAstraZenecaPhase 3
40
MEDI3250 + PlaceboAstraZenecaPhase 3
40
MEDI3250AstraZenecaPhase 3
40
Budesonide Formoterol Drug Combination + nebulisation of terbutalineAstraZenecaPhase 3
32
Saizen® A + Saizen® BMerckPhase 3
40
RotaTeq (V260) + IPVMerckPhase 3
40
HydroxyureaNovartisPhase 3
47
Norditropin® FlexPro®Novo NordiskPre-clinical
33
Somapacitan + Norditropin®Novo NordiskPhase 3
40
Somapacitan + Norditropin®Novo NordiskPhase 2
39
somapacitan + Norditropin®Novo NordiskPhase 3
40
SomapacitanNovo NordiskPre-clinical
33
VoxelotorPfizerPhase 2
27
Sildenafil citrate + Sildenafil citrate + Placebo + Sildenafil citratePfizerPhase 3
40
Copanlisib (BAY806946)BayerPhase 1/2
21
EptinezumabLundbeckPhase 1
26
Eptinezumab + PlaceboLundbeckPhase 3
44